XGN - Exagen Inc Stock Price, Fair Value and News

1.88USD-0.01 (-0.53%)Market Closed

Market Summary

USD1.88-0.01

Market Closed

-0.53%

XGN Stock Price

View Fullscreen

XGN RSI Chart

XGN Valuation

Market Cap

32.7M

Price/Earnings (Trailing)

-1.69

Price/Sales (Trailing)

0.59

Price/Free Cashflow

-2.29

XGN Price/Sales (Trailing)

XGN Profitability

Return on Equity

-96.85%

Return on Assets

-38.11%

Free Cashflow Yield

-43.69%

XGN Fundamentals

XGN Revenue

Revenue (TTM)

55.7M

Rev. Growth (Yr)

28.36%

Rev. Growth (Qtr)

4.72%

XGN Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

56.3%

Earnings Growth (Qtr)

39.71%

Breaking Down XGN Revenue

Last 7 days

34.0%

Last 30 days

31.3%

Last 90 days

-11.7%

Trailing 12 Months

-41.7%

How does XGN drawdown profile look like?

XGN Financial Health

Current Ratio

4.83

Debt/Equity

0.96

Debt/Cashflow

-0.71

XGN Investor Care

Shares Dilution (1Y)

3.26%

Diluted EPS (TTM)

-1.09

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	55.7M	0	0	0
2023	46.4M	52.9M	51.6M	52.5M
2022	48.1M	42.9M	45.4M	45.6M
2021	43.0M	46.8M	48.3M	48.3M
2020	40.7M	39.2M	39.5M	42.0M
2019	34.4M	36.4M	38.4M	40.4M
2018	0	0	0	32.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Exagen Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 04, 2024	adawi kamal	sold	-24,406	1.90917	-12,784	cfo and corporate secretary
Feb 29, 2024	aballi john	acquired	18,725	1.91	9,804	president and ceo
Feb 20, 2024	adawi kamal	acquired	-	-	75,000	cfo and corporate secretary
Feb 20, 2024	aballi john	acquired	-	-	175,000	president and ceo
Feb 06, 2024	adawi kamal	sold	-13,133	1.9491	-6,738	cfo and corporate secretary
Oct 17, 2023	aballi john	sold	-59,017	1.7451	-33,819	president and ceo
Aug 31, 2023	aballi john	acquired	20,998	2.142	9,803	president and ceo
Jun 15, 2023	tullis james l l	bought	519	3.1105	167	-
Mar 02, 2023	adawi kamal	sold	-8,431	2.2993	-3,667	cfo and corporate secretary
Mar 02, 2023	hazeltine mark	sold	-	-	-3,667	chief business officer

Which funds bought or sold XGN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	reduced	-17.81	-23,016	44,029	-%
May 15, 2024	CITADEL ADVISORS LLC	reduced	-65.08	-29,751	11,512	-%
May 15, 2024	Royal Bank of Canada	reduced	-83.76	-1,000	-	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-16,320	64,872	-%
May 15, 2024	SILVERCREST ASSET MANAGEMENT GROUP LLC	unchanged	-	-217,951	866,354	0.01%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	1.04	-9,057	37,937	-%
May 15, 2024	Stonepine Capital Management, LLC	reduced	-42.57	-721,157	611,514	0.48%
May 15, 2024	Nantahala Capital Management, LLC	reduced	-61.75	-268,407	118,147	0.01%
May 15, 2024	RTW INVESTMENTS, LP	unchanged	-	-601,841	2,392,320	0.04%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-19.1	-3,485	6,369	-%

Are Funds Buying or Selling XGN?

Are funds buying XGN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XGN

No. of Funds

Unveiling Exagen Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	rtw investments, lp	8.8%	1,504,602	SC 13G/A
Feb 14, 2024	lytton laurence w	6.8%	1,153,488	SC 13G/A
Feb 13, 2024	stonepine capital management, llc	3.9%	669,684	SC 13G/A
Feb 13, 2024	tullis dickerson capital focus iii, l.p.	6.5%	1,112,357	SC 13G/A
Feb 09, 2024	wasatch advisors lp	-	0	SC 13G/A
Feb 02, 2024	cowen financial products llc	5.27%	898,630	SC 13G/A
Jan 22, 2024	nmsic co-investment fund, l.p.	13.55%	2,308,958	SC 13G/A
Feb 14, 2023	rtw investments, lp	8.4%	1,364,336	SC 13G/A
Feb 13, 2023	stonepine capital management, llc	5.2%	854,042	SC 13G/A
Feb 13, 2023	lytton laurence w	5.3%	871,181	SC 13G/A

Recent SEC filings of Exagen Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
May 13, 2024	S-8	Employee Benefits Plan
Apr 26, 2024	8-K	Current Report
Apr 26, 2024	ARS	ARS
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	DEFA14A	DEFA14A
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	10-K	Annual Report

Peers (Alternatives to Exagen Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
DHR	196.9B	23.7B	10.13%	17.51%	44.73	8.29	-8.94%	-35.91%
A	45.2B	6.7B	12.76%	20.73%	36.57	6.71	-2.81%	-6.58%
IDXX	44.9B	3.7B	10.56%	11.11%	51.83	12.06	8.57%	23.94%
DGX	16.0B	9.3B	11.84%	7.84%	18.95	1.73	-3.29%	6.68%
NTRA	13.1B	1.2B	20.21%	118.71%	-35.76	10.81	39.26%	33.08%
MEDP	12.2B	2.0B	2.04%	87.82%	38.94	6.2	25.57%	21.62%
CRL	11.4B	4.1B	-3.32%	14.15%	26.02	2.78	0.49%	-11.59%
EXAS	9.3B	2.5B	-18.63%	-33.92%	-38.69	3.67	15.21%	53.51%
MID-CAP
GH	3.1B	603.7M	62.38%	-9.67%	-6.73	5.14	25.21%	30.68%
NEOG	2.9B	929.2M	10.28%	-20.84%	1.9K	3.16	28.93%	111.61%
SMALL-CAP
CDNA	808.3M	275.1M	88.15%	90.09%	-4.41	2.94	-13.93%	-126.97%
ACRS	84.8M	31.1M	-4.10%	-85.92%	-1.1	2.73	0.95%	19.75%
AWH	33.0M	9.2M	-21.45%	-32.59%	-2.24	3.6	11.85%	45.80%
APDN	2.5M	5.5M	708.82%	139.13%	-0.2	0.45	-68.52%	-141.15%
BIOC	183.8K	25.9M	-50.00%	-94.83%	-0.01	0.01	-57.78%	-93.11%

Exagen Inc News

Latest updates

Exagen Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	4.7%	14,415	13,765	13,416	14,137	11,230	12,837	14,726	7,606	10,394	12,689	12,251	12,772	10,587	12,668	10,775	8,948	9,584	10,214	10,439	10,474	9,260
Costs and Expenses	-7.9%	17,418	18,912	18,485	19,052	18,936	27,328	22,543	21,670	20,073	18,943	18,755	18,514	16,154	15,429	14,561	12,365	14,805	13,072	12,596	12,884	11,134
S&GA Expenses	-13.7%	10,542	12,216	11,375	11,953	11,884	12,812	14,151	12,903	12,152	11,802	11,528	11,171	10,040	9,929	9,202	8,276	9,626	7,915	7,306	7,302	6,179
R&D Expenses	-1.6%	1,059	1,076	1,400	1,263	1,126	2,701	2,382	2,689	2,104	2,202	1,740	1,892	1,403	1,165	1,018	751	634	566	507	590	513
Interest Expenses	-3.0%	549	566	557	574	638	626	618	606	598	639	678	663	645	652	647	635	631	771	909	910	901
Income Taxes	-	-	-	-	-	-	-	-	-	-	175	-	-	-	39.00	-	-	-118	25.00	-	-	-
Net Income	39.7%	-3,360	-5,573	-5,415	-5,013	-7,688	-14,354	-8,096	-14,665	-10,272	-7,053	-7,179	-6,410	-6,209	-3,453	-4,308	-3,363	-5,563	-3,408	-3,141	-2,785	-2,704
Net Income Margin	22.9%	-0.35*	-0.45*	-0.63*	-0.66*	-0.97*	-1.04*	-0.88*	-0.91*	-0.64*	-0.56*	-0.48*	-0.44*	-0.40*	-	-	-	-	-	-	-	-
Free Cashflow	-210.7%	-9,126	8,243	-2,910	-10,478	-10,145	-6,140	-7,561	-13,100	-9,661	-7,111	-5,885	-5,164	-4,479	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-10.8%	51.00	57.00	61.00	64.00	79.00	86.00	102	107	122	123	128	133	138	78.00	80.00	81.00	85.00	88.00	93.00	29.00
Current Assets	-11.4%	42.00	48.00	49.00	51.00	66.00	73.00	82.00	88.00	104	113	118	125	129	71.00	73.00	73.00	78.00	81.00	86.00	21.00
Cash Equivalents	-24.7%	27.00	36.00	28.00	31.00	52.00	62.00	69.00	76.00	90.00	100	107	113	118	58.00	62.00	64.00	69.00	72.00	78.00	13.00
Net PPE	-	-	-	-	-	-	-	-	-	-	5.00	3.00	3.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	2.00
Goodwill	-	-	-	-	-	-	-	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00	6.00
Liabilities	-10.0%	31.00	34.00	33.00	32.00	43.00	44.00	45.00	44.00	46.00	39.00	37.00	37.00	36.00	37.00	36.00	33.00	34.00	33.00	34.00	36.00
Current Liabilities	-26.2%	9.00	12.00	10.00	9.00	9.00	10.00	11.00	10.00	12.00	9.00	8.00	8.00	8.00	9.00	8.00	6.00	7.00	6.00	8.00	9.00
Long Term Debt	0.2%	19.00	19.00	19.00	19.00	29.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	25.00
LT Debt, Current	1.5%	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	-100.0%	-	19.00	19.00	19.00	29.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	27.00	26.00	26.00	26.00	26.00	26.00	25.00
Shareholder's Equity	-11.9%	20.00	23.00	28.00	32.00	36.00	42.00	56.00	63.00	76.00	85.00	91.00	96.00	101	42.00	44.00	48.00	51.00	56.00	59.00	-
Retained Earnings	-1.2%	-282	-279	-273	-268	-263	-255	-241	-233	-218	-208	-201	-193	-187	-181	-177	-173	-170	-164	-161	-152
Additional Paid-In Capital	0.2%	303	302	301	300	299	298	297	296	295	293	292	290	289	223	222	221	221	220	220	41.00
Shares Outstanding	1.6%	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	17.00	16.00	16.00	15.00	13.00	-	-	-	-	-	-	-
Float	-	-	-	-	37.00	-	-	-	62.00	-	-	-	158	-	-	-	83.00	-	-	105	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-208.3%	-9,040	8,349	-2,908	-10,154	-9,749	-5,734	-6,682	-11,154	-8,574	-6,047	-5,460	-4,450	-4,312	-3,899	-2,128	-4,756	-3,301	-3,927	-1,666	-2,168	-1,950
Share Based Compensation	-27.5%	553	763	890	978	986	582	1,306	1,440	1,376	1,177	1,354	1,285	912	817	799	647	431	487	62.00	11.00	12.00
Cashflow From Investing	-2.4%	-86.00	-84.00	-2.00	-322	-396	-406	-879	-1,946	-1,087	-1,064	-475	-714	-167	-5.00	-213	-153	-84.00	-26.00	-2.00	288	-363
Cashflow From Financing	54.5%	-100	-220	-108	-10,242	-62.00	-173	-22.00	-264	-30.00	-213	125	-310	65,081	-82.00	75.00	-39.00	-51.00	-1,791	63,259	3,790	3,476

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XGN Income Statement

2024-03-31

Unaudited Condensed Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Statement [Abstract]
Revenue	$ 14,415	$ 11,230
Operating expenses:
Costs of revenue	5,817	5,926
Selling, general and administrative expenses	10,542	11,884
Research and development expenses	1,059	1,126
Total operating expenses	17,418	18,936
Loss from operations	(3,003)	(7,706)
Interest expense	(549)	(638)
Interest income	192	656
Net loss	$ (3,360)	$ (7,688)
Net loss per share, basic (in dollars per share)	$ (0.19)	$ (0.44)
Net loss per share, diluted (in dollars per share)	$ (0.19)	$ (0.44)
Weighted-average number of shares used to compute net loss per share, basic (in shares)	17,944,438	17,526,763
Weighted-average number of shares used to compute net loss per share, diluted (in shares)	17,944,438	17,526,763

XGN Balance Sheet

2024-03-31

Unaudited Condensed Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 27,267	$ 36,493
Accounts receivable, net	10,901	6,551
Prepaid expenses and other current assets	4,232	4,797
Total current assets	42,400	47,841
Property and equipment, net	4,775	5,201
Operating lease right-of-use assets	3,072	3,286
Other assets	561	616
Total assets	50,808	56,944
Current liabilities:
Accounts payable	1,470	3,131
Accrued and other current liabilities	6,040	7,531
Operating lease liabilities	1,005	976
Borrowings-current portion	268	264
Total current liabilities	8,783	11,902
Borrowings-non-current portion, net of discounts and debt issuance costs	19,269	19,231
Non-current operating lease liabilities	2,497	2,760
Other non-current liabilities	268	357
Total liabilities	30,817	34,250
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized, no shares issued or outstanding as of March 31, 2024 and December 31, 2023	0	0
Common stock, $0.001 par value per share; 200,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 17,317,941 and 17,045,954 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	17	17
Additional paid-in capital	302,550	301,893
Accumulated deficit	(282,576)	(279,216)
Total stockholders' equity	19,991	22,694
Total liabilities and stockholders' equity	$ 50,808	$ 56,944

About Exagen Inc

Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

CEO	Mr. John Aballi
WEBSITE	exagen.com
INDUSTRY	Diagnostics & Research
EMPLOYEES	199

Exagen Inc Frequently Asked Questions

What is the ticker symbol for Exagen Inc? What does XGN stand for in stocks?

XGN is the stock ticker symbol of Exagen Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exagen Inc (XGN)?

As of Thu May 16 2024, market cap of Exagen Inc is 32.84 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XGN stock?

You can check XGN's fair value in chart for subscribers.

What is the fair value of XGN stock?

You can check XGN's fair value in chart for subscribers. The fair value of Exagen Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Exagen Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XGN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Exagen Inc a good stock to buy?

The fair value guage provides a quick view whether XGN is over valued or under valued. Whether Exagen Inc is cheap or expensive depends on the assumptions which impact Exagen Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XGN.

What is Exagen Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, XGN's PE ratio (Price to Earnings) is -1.7 and Price to Sales (PS) ratio is 0.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XGN PE ratio will change depending on the future growth rate expectations of investors.